ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)  M. Mikulska, S. Lanini, C. Gudiol, L. Drgona, G. Ippolito, M. Fernández-Ruiz, B. Salzberger  Clinical Microbiology and Infection  Volume 24, Pages S71-S82 (June 2018) DOI: 10.1016/j.cmi.2018.02.003 Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Mode of action of blinatumomab, a first-in-class bispecific T-cell engager (BiTE) engineered using a diabody approach. This agent results from combining two variable regions (VH and VL) of normal antibodies with different specificities. One of these region binds to CD3 on the surface of cytotoxic T cells, while the other binds to CD19, which is largely expressed on the majority of B precursor acute lymphoblastic leukaemia blasts. The elimination of the constant regions of these antibodies allows for close approximation of both cells, thereby facilitating T-cell-mediated killing of the bound malignant B cells. Clinical Microbiology and Infection 2018 24, S71-S82DOI: (10.1016/j.cmi.2018.02.003) Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions